• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form 144/A filed by Ionis Pharmaceuticals Inc.

    3/24/26 4:43:45 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IONS alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144/A

    144/A: Filer Information

    Filer CIK
    0001838539
    Filer CCC
    XXXXXXXX
    Previous Accession Number Of The Filing
    0001972481-26-000114
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144/A: Issuer Information

    Name of Issuer
    IONIS PHARMACEUTICALS INC
    SEC File Number
    000-19125
    Address of Issuer
    2855 GAZELLE COURT
    CARLSBAD
    CALIFORNIA
    92010
    Phone
    7609319200
    Name of Person for Whose Account the Securities are To Be Sold
    Schneider Eugene
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144/A: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common Stock
    Stifel Nicolaus & Company Inc
    501 N Broadway
    St. Louis � MO � 63102
    5812412486.0016519000003/19/2026
    Nasdaq


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144/A: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common Stock01/15/2026Performance Stock UnitsIssuerCheckbox not checked581201/15/2026Equity Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144/A: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Eugene Schneider
    2855 Gazelle Ct
    Carlsbad � CA � 92010
    Common Stock01/30/20266179512906.00
    Eugene Schneider
    2855 Gazelle Ct
    Carlsbad � CA � 92010
    Common Stock01/16/20269302703138.00

    144/A: Remarks and Signature

    Remarks
    Date of Notice
    03/24/2026
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    11/19/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ James Weimer, as a duly authorized representative of STIFEL, as attorney-in-fact for Eugene Schneider

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $IONS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IONS

    DatePrice TargetRatingAnalyst
    5/19/2026$115.00Buy
    Citigroup
    4/21/2026$110.00Buy
    Canaccord Genuity
    4/10/2026$104.00Outperform
    Raymond James
    1/28/2026$95.00Overweight
    Barclays
    10/8/2025$80.00Neutral → Overweight
    Analyst
    9/26/2025$65.00Sell → Neutral
    Goldman
    9/3/2025$70.00Market Perform → Outperform
    BMO Capital Markets
    7/31/2025$62.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings

    $IONS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on Ionis Pharma with a new price target

    Citigroup initiated coverage of Ionis Pharma with a rating of Buy and set a new price target of $115.00

    5/19/26 8:31:24 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on Ionis Pharma with a new price target

    Canaccord Genuity initiated coverage of Ionis Pharma with a rating of Buy and set a new price target of $110.00

    4/21/26 7:33:40 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James resumed coverage on Ionis Pharma with a new price target

    Raymond James resumed coverage of Ionis Pharma with a rating of Outperform and set a new price target of $104.00

    4/10/26 12:22:24 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IONS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Berthelsen Spencer R exercised 8,000 shares at a strike of $24.42 and sold $605,360 worth of shares (8,000 units at $75.67) as part of a pre-agreed trading plan (SEC Form 4)

    4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

    6/3/26 5:34:36 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Monia Brett P exercised 4,536 shares at a strike of $32.60 and sold $356,012 worth of shares (4,536 units at $78.49) as part of a pre-agreed trading plan (SEC Form 4)

    4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

    5/15/26 6:15:03 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Loscalzo Joseph exercised 77,289 shares at a strike of $48.74 and sold $5,801,226 worth of shares (77,289 units at $75.06) as part of a pre-agreed trading plan (SEC Form 4)

    4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

    5/6/26 5:27:00 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IONS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B

    – Pivotal B-Well data show significant 19% functional cure rate in the overall study population and 26% in patients with lower viral activity, compared to 0% with standard of care – – 49% of bepirovirsen recipients achieved a surface antigen level of ≤100 IU/mL one year after end of treatment in exploratory analysis – – A loss in surface antigen is associated with a significant reduction in risk of liver cancer – – Over 240 million people worldwide live with chronic hepatitis B – Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) partner GSK today announced positive pivotal data for bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of chronic hepatitis B (CHB

    5/28/26 4:45:00 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer's disease

    - Based on the strength of the biomarker and efficacy data, Biogen plans to advance diranersen to registrational development; CELIA did not meet its primary endpoint assessing dose response - - Robust reductions in tau pathology were observed across all studied doses, with results generally consistent with those observed in the Phase 1b study - - Pre-specified analyses of cognitive endpoints demonstrated slowing of clinical decline across all studied doses, particularly at the lowest dose - - The safety and tolerability profile of diranersen was generally consistent with the Phase 1b study - - Data will be presented at the Alzheimer's Association International Conference (AAIC) 2026

    5/14/26 7:05:00 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ionis to host 2026 virtual Annual Meeting of Stockholders

    Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that management will conduct its 2026 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 4, 2026. The agenda for the event is as follows: 5:00 p.m. – 5:15 p.m. ET (2:00 p.m. – 2:15 p.m. PT) – Virtual Annual Meeting of Stockholders All stockholders of record at the close of business on April 7, 2026, are invited to participate in the virtual Annual Meeting webcast, which will be broadcast live at www.virtualshareholdermeeting.com/IONS2026. Stockholders of record will receive an official proxy card or notice from their brokerage firm. Each proxy card/notice contains a 16-digit cont

    5/4/26 7:05:00 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IONS
    SEC Filings

    View All

    Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)

    5/28/26 12:41:22 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Ionis Pharmaceuticals Inc.

    10-Q - IONIS PHARMACEUTICALS INC (0000874015) (Filer)

    4/29/26 2:33:38 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)

    4/29/26 7:00:32 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IONS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hayden Michael R bought $477,900 worth of shares (15,000 units at $31.86), increasing direct ownership by 43% to 50,219 units (SEC Form 4)

    4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

    5/2/25 4:38:26 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hayden Michael R bought $181,079 worth of shares (5,000 units at $36.22), increasing direct ownership by 17% to 35,219 units (SEC Form 4)

    4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

    12/26/24 4:57:52 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IONS
    Leadership Updates

    Live Leadership Updates

    View All

    Ionis announces changes to Board of Directors

    – Lynne Parshall and Joseph Wender to retire at end of term in June 2026 and Peter Reikes to join Ionis Board – Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced upcoming transitions on its Board of Directors. B. Lynne Parshall, Esq., and Joseph Wender will be retiring at the end of their term and Peter N. Reikes will be rejoining as a director. The changes will be effective June 4, 2026. Ms. Parshall has served as a director since September 2000. Previously, she served as Ionis' chief operating officer from December 2007 through December 2017 and as chief financial officer from June 1994 through December 2012. Ms. Parshall joined Ionis in 1991 and served in various executive ro

    3/9/26 7:00:00 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alltrna Announces Updates to Its Board of Directors

    Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera

    7/17/24 8:00:00 AM ET
    $APRE
    $CYTK
    $EVLO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Biotechnology: Biological Products (No Diagnostic Substances)

    Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

    Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut

    6/24/24 4:05:00 PM ET
    $CTNM
    $IONS
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals
    Medicinal Chemicals and Botanical Products

    $IONS
    Financials

    Live finance-specific insights

    View All

    Ionis reports first quarter 2026 financial results and highlights progress on key programs

    - TRYNGOLZA® (olezarsen) showed increasing demand in FCS driven by strong launch execution – - Olezarsen sNDA accepted by the FDA for Priority Review; sHTG launch preparations on track – – Increasing annual TRYNGOLZA peak net sales guidance to >$3B for sHTG – - Zilganersen NDA for Alexander disease accepted for Priority Review, paving way for Ionis' first independent launch from leading neurology pipeline – - Strong first-quarter performance and outlook for the year supports improved 2026 financial guidance - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company") today reported financial results and provided key updates for the first quarter ended March 31, 2026. "Ionis' stro

    4/29/26 7:00:00 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs

    - TRYNGOLZA® generated $108 million in net product sales in 2025, the first year of launch – - Olezarsen sHTG launch preparations on track, sNDA submitted - - Exceeded 2025 financial guidance, 2026 guidance reflects commitment to independently deliver a steady cadence of innovative medicines to patients - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company") today reported financial results and provided key updates for the fourth quarter and year ended December 31, 2025. "2025 was a defining year for Ionis, marked by the successful execution of our first two independent launches and multiple positive data readouts across our pipeline, positioning Ionis for continued success in 2

    2/25/26 7:00:00 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biogen Completes Acquisition of Alcyone Therapeutics

    CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) has completed the acquisition of Alcyone Therapeutics, a clinical-stage biotechnology company known for its innovative CNS therapy delivery solutions, such as the ThecaFlex DRx™ drug delivery system. ThecaFlex DRx™ is an investigational implantable device designed to provide an alternative to repeat lumbar punctures in chronic intrathecal administration of medicines, which could ease both patient experience and accessibility for a broader population of people living with neurologic disorders. ThecaFlex DRx™ has been in development since 2019, with the PIERRE and PIERRE-PK clinical studies for nusinersen curren

    11/14/25 4:05:00 PM ET
    $BIIB
    $IONS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $IONS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ionis Pharmaceuticals Inc.

    SC 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

    11/14/24 8:34:57 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ionis Pharmaceuticals Inc.

    SC 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

    11/14/24 1:28:29 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Ionis Pharmaceuticals Inc.

    SC 13G - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

    11/8/24 10:52:38 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care